Please assess the completion status of the following clinical trial:

Trial Title: Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of histologically documented MM with relapsed or progressive disease after at least one line of prior therapy.~* Patient has measurable disease in which to capture response, defined as one or more of the following:~  * Serum M-protein level \> 1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis; or~ * Urinary M-protein excretion \> 1000 mg/24 hours; or~ * Bone marrow plasmacytosis of \> 30% by bone marrow aspirate and/or biopsy; or~ * Serum free light chains (by the Freelite test) \> 2 X the upper limit of normal, in the absence of renal failure.~ * Evidence of active disease by radiographic techniques~* Performance status (PS) of \<= 2 as per Southwest Oncology Group scale, unless PS of 3-4 based solely on bone pain.~* Patients must have a platelet count \>= 50,000/mm3, and an absolute neutrophil count of at least 1,000/μl.~* Patients must have adequate renal function defined as creatinine clearance \> 30ml/min.~* Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin \< 2 X the upper limit of normal.~* Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy test documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.~* Male or female adults of at least 18 years of age.~* Patients must have signed and Institutional Review Board approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations~Exclusion Criteria:~* Chemotherapy or radiotherapy received within the previous 4 weeks.~* Has received previous bortezomib therapy~* Significant neurotoxicity, defined as grade \> 2 neurotoxicity per National Cancer Institute Common Toxicity Criteria.~* Platelet count \< 50,000/mm3, or ANC \< 1,000/μl~* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome.~* Patient has hypersensitivity to bortezomib, boron, or mannitol~* Clinically significant hepatic dysfunction as noted by bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis.~* New York Hospital Association Class III or Class IV heart failure.~* Myocardial infarction within the last 6 months.~* Non-secretory multiple myeloma, unless the patient has measurable lesions on computed tomography, magnetic resonance imaging and/or positron emission tomography.~* Uncontrolled, active infection.~* Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias.~* Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.~* Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy \[beta-HCG\] test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each cycle of study drug.~* Breast-feeding women may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Velcade, Cohort A (Type: EXPERIMENTAL): Treatment: 1.3 mg/m\^2
- Velcade, Cohort B (Type: EXPERIMENTAL): Treatment: 1.0 mg/m\^2
- Velcade, Cohort C (Type: EXPERIMENTAL): Treatment: 0.7 mg/m\^2

Based on this trial design, predict the completion outcome and termination type (if applicable).